UPDATE 1-Orexigen to unveil obesity trial results on Monday
* Conference call scheduled for Monday
* Shares rise 1.6 percent after hours
LOS ANGELES, July 17 (Reuters) - Orexigen Therapeutics Inc (OREX.O) will release early on Monday results of the three remaining pivotal trials of its experimental obesity drug, Contrave.
The San Diego-based company said in a statement on Friday that it also will hold a conference call on Monday to discuss the data.
Orexigen announced in January that its first late-stage trial found that obese patients treated with Contrave lost an average 9.3 percent of their weight, but the results fell short of a bar set by regulators and Wall Street was disappointed.
Contrave is a pill that combines the antidepressant Wellbutrin, known generically as bupropion, with a sustained- release version of naltrexone, an opioid antagonist used to treat alcoholism and other addictions.
Shares of Orexigen, which rose 4.4 percent to close at $5.69 on Nasdaq, were up another 1.6 percent at $5.78 after hours. (Reporting by Deena Beasley; editing by Carol Bishopric)